Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Pusztai L, et al. Among authors: yee d. Cancer Cell. 2021 Jul 12;39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. Epub 2021 Jun 17. Cancer Cell. 2021. PMID: 34143979 Free PMC article. Clinical Trial.
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. Wolf DM, et al. Among authors: yee d. NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017. NPJ Breast Cancer. 2017. PMID: 28948212 Free PMC article.
Gender differences in pain interference with daily activities and functional impairment among patients with hidradenitis suppurativa: A population-based study in the United States.
Kingston P, Peterson H, Lee K, Huang MY, Yee D, Korouri E, Armstrong AW. Kingston P, et al. Among authors: yee d. J Eur Acad Dermatol Venereol. 2025 Jan 7. doi: 10.1111/jdv.20518. Online ahead of print. J Eur Acad Dermatol Venereol. 2025. PMID: 39775852 No abstract available.
International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting.
Zhang AJ, Ball G, Zundell MP, Agüero R, Yee D, Shields A, Asare C, Navrazhina K, Liu W, Foolad N, Kwock J, Tejwani P, Hamade H, Jaleel T, Butler D, Silverberg N, Nattkemper L, Siegel DM, Tan J, Kim BS, Larocca C, Shinohara MM, Ehlert A, Latella J, Guttman-Yassky E, Krueger JG, Strand V, Armstrong AW, Merola JF, Perez-Chada L, Gottlieb AB. Zhang AJ, et al. Among authors: yee d. J Drugs Dermatol. 2024 Dec 1;23(12):1114-1120. doi: 10.36849/jdd.8363. J Drugs Dermatol. 2024. PMID: 39630678
840 results